Table 2. Association of rs2298881C>A and rs6519214G>T and survival outcomes in the discovery and validation sets.
| ID No.* | Genotypes | Discovery cohort | Validation cohort | Combined cohort | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall survival | Disease-free survival | Overall survival | Disease-free survival | Overall survival | Disease-free survival | ||||||||
| HR (95%CI)† | P† | HR (95%CI)† | P† | HR (95%CI)† | P† | HR (95%CI)† | P† | HR (95%CI)† | P† | HR (95%CI)† | P† | ||
| rs2298881‡ | CC | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| CA | 1.18 (0.75−1.86) | 0.47 | 1.07 (0.73−1.57) | 0.73 | 1.47 (0.97−2.23) | 0.07 | 1.26 (0.95−1.68) | 0.11 | 1.30 (0.96−1.75) | 0.09 | 1.19 (0.95−1.49) | 0.13 | |
| AA | 1.92 (1.15−3.20) | 0.01 | 1.59 (1.01−2.48) | 0.04 | 2.00 (1.26−3.16) | 0.003 | 1.31 (0.93−1.84) | 0.13 | 1.88 (1.34−2.63) | 0.000 | 1.38 (1.05−1.80) | 0.02 | |
| Dominant | 1.37 (0.90−2.09) | 0.14 | 1.20 (0.84−1.72) | 0.31 | 1.63 (1.10−2.42) | 0.02 | 1.28 (0.98−1.67) | 0.08 | 1.46 (1.10−1.94) | 0.01 | 1.24 (1.00−1.54) | 0.05 | |
| Recessive | 1.73 (1.14−2.63) | 0.01 | 1.52 (1.04−2.22) | 0.03 | 1.55 (1.09−2.19) | 0.01 | 1.12 (0.85−1.49) | 0.42 | 1.58 (1.21−2.06) | 0.001 | 1.23 (0.98−1.54) | 0.07 | |
| Additive | 1.39 (1.06−1.81) | 0.02 | 1.25 (0.99−1.58) | 0.06 | 1.41 (1.13−1.77) | 0.003 | 1.15 (0.97−1.36) | 0.11 | 1.37 (1.16−1.63) | 0.000 | 1.17 (1.03−1.34) | 0.02 | |
| rs6509214§ | GG | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| GT | 1.47 (0.97−2.24) | 0.07 | 1.63 (1.13−2.37) | 0.01 | 0.91 (0.60−1.38) | 0.65 | 0.97 (0.71−1.31) | 0.82 | 1.17 (0.87−1.57) | 0.30 | 1.21 (0.95−1.52) | 0.12 | |
| TT | 1.67 (0.94−2.97) | 0.08 | 1.61 (0.97−2.67) | 0.06 | 0.87 (0.51−1.49) | 0.61 | 0.75 (0.50−1.12) | 0.16 | 1.10 (0.75−1.61) | 0.64 | 0.99 (0.73−1.35) | 0.95 | |
| Dominant | 1.51 (1.01−2.26) | 0.05 | 1.63 (1.14−2.33) | 0.01 | 0.90 (0.60−1.33) | 0.59 | 0.90 (0.67−1.20) | 0.45 | 1.15 (0.87−1.52) | 0.33 | 1.14 (0.91−1.43) | 0.24 | |
| Recessive | 1.31 (0.80−2.16) | 0.29 | 1.18 (0.76−1.83) | 0.45 | 0.93 (0.58−1.48) | 0.75 | 0.77 (0.54−1.09) | 0.14 | 1.00 (0.71−1.40) | 0.99 | 0.89 (0.68−1.16) | 0.38 | |
| Additive | 1.32 (1.01−1.73) | 0.05 | 1.32 (1.04−1.66) | 0.02 | 0.93 (0.72−1.21) | 0.59 | 0.88 (0.73−1.06) | 0.19 | 1.06 (0.89−1.28) | 0.52 | 1.02 (0.88−1.18) | 0.78 | |
Abbreviations: HR, hazard ratio; CI, confidence interval.
*
Information about polymorphisms and IDs were obtained from NCBI database (http://www.ncbi.nlm.nih.gov/SNP).
†
HRs, 95% CIs and their corresponding P-values were calculated using multivariate Cox proportional hazard models, adjusted for age, gender, smoking status, tumor histology, pathologic stage, adjuvant therapy.
‡
The numbers of patients in discovery, validation, and combined cohort for rs2298881 were 316, 579, and 895, respectively.
§
The numbers of patients in discovery, validation, and combined cohort for rs6509214 were 316, 412, and 728, respectively, due to lack of available samples for validation.